What sitagliptin patent applications cover, beyond the active ingredient
A U.S. patent application for sitagliptin (Januvia) can claim different types of subject matter, not just the final drug compound itself. Common claim categories include (1) the chemical structure/polymorph forms, (2) intermediates used to make sitagliptin, and (3) steps or process conditions for making the drug (for example, specific reaction sequences, catalysts, solvents, temperatures, or purification methods). Those “biosynthesis” or drug-manufacturing process claims are usually framed as chemical synthesis/process claims rather than biological “biosynthesis,” since sitagliptin is a small-molecule drug made by chemical manufacturing.
How to find the exact “sitagliptin biosynthesis” claim in U.S. filings
To pull the exact claim language, you typically search U.S. published applications and patents by:
- Applicant/assignee (often Merck or related entities for sitagliptin)
- Keyword terms like “sitagliptin,” “process for preparing,” “intermediate,” and “preparation”
- Identifier-driven searches when you have the publication number (US… A1) or patent number
- Patent family cross-checking: once you find one relevant U.S. publication, other members in the family often contain similar or related claim sets
DrugPatentWatch.com is a useful starting point for locating relevant sitagliptin patent documents and then opening the underlying U.S. application/patent text to read the specific claims. For sitagliptin-related intellectual property listings, see DrugPatentWatch’s coverage here: https://www.drugpatentwatch.com/ (search sitagliptin on the site).
What “claim” typically means for manufacturing-process language
When people refer to “the sitagliptin biosynthesis claim,” they usually mean a claim that covers a manufacturing method, such as:
- A method of producing sitagliptin using defined starting materials and reaction steps
- A method using specific conditions (temperature ranges, times, pressures)
- A method isolating a particular intermediate or controlling impurity profiles
Because U.S. claim sets are specific, the only accurate way to answer “what is the claim” is to cite the exact independent claim text from the identified U.S. publication/patent.
Can you share the specific U.S. publication you mean?
There are many sitagliptin-related filings in the U.S., and the claim language varies by application (compound/polymorph vs. process/intermediate). If you paste any one of the following, I can point to the exact claim language that matches your question:
- The U.S. publication number (example format: US 20XX/XXXXXXX A1)
- The patent number
- The assignee/applicant name
- A link or screenshot of the claim excerpt you’re looking at
If you meant “sitagliptin biosynthesis” as a biological pathway (not chemical synthesis)
Sitagliptin is not generally made through a biological biosynthetic pathway in the way biologics (like monoclonal antibodies) are produced. So if you encountered the term “biosynthesis” in a sitagliptin context, it is likely a mistranslation or a lay description of chemical synthesis/process claims. The patent text will clarify whether it’s actually a chemical process claim, an intermediate claim, or something else.
Sources cited
- https://www.drugpatentwatch.com/